round button
Leave a message

Mexico Specific Pollen Allergies Market Analysis

Request for TOC Request for TOC Speak to Analyst Speak to Analyst Buy Now Buy Now Inquire Before Buying Inquire Before Free Sample Report Free Sample Report

Mexico Specific Pollen Allergies Market Analysis

  • Pharmaceutical
  • Published Report
  • Sep 2022
  • Country Level
  • 350 Pages
  • No of Tables: 22
  • No of Figures: 19

Table of Content

1 INTRODUCTION

1.1 OBJECTIVES OF THE STUDY

1.2 MARKET DEFINITION

1.3 OVERVIEW OF MEXICO SPECIFIC POLLEN ALLERGIES MARKET

1.4 LIMITATIONS

1.5 MARKETS COVERED

2 MARKET SEGMENTATION

2.1 MARKETS COVERED

2.2 GEOGRAPHICAL SCOPE

2.3 YEARS CONSIDERED FOR THE STUDY

2.4 CURRENCY AND PRICING

2.5 DBMR TRIPOD DATA VALIDATION MODEL

2.6 MULTIVARIATE MODELLING

2.7 PRODUCT TYPE LIFELINE CURVE

2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS

2.9 DBMR MARKET POSITION GRID

2.1 MARKET END USER COVERAGE GRID

2.11 VENDOR SHARE ANALYSIS

2.12 SECONDARY SOURCES

2.13 ASSUMPTIONS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

4.1 PESTEL ANALYSIS

4.2 PORTER’S FIVE FORCES MODEL

4.3 CURRENT PATENTS THAT CAN BE USED IN ALLOPATHIC MEDICINES IN MEXICO-

4.4 INVENTION PATENT-

4.5 COUNTRY LEVEL ANALYSIS

5 REGULATIONS

5.1 MEXICO

6 MARKET OVERVIEW

6.1 DRIVERS

6.1.1 INCREASE IN PREVALENCE OF ALLERGIC DISORDER

6.1.2 WIDE RANGE OF PRODUCT PORTFOLIOS OFFERED BY MAJOR PLAYER

6.1.3 IMPACT OF POLLEN ALLERGIES ON PAEDIATRICS POPULATION

6.1.4 HEALTH SECTOR REFORM AND EXPANSION OF PROGRAMMES TO BOOST HEALTHCARE SPENDING

6.2 RESTRAINTS

6.2.1 SIDE EFFECTS ASSOCIATED WITH THE USE OF DRUGS

6.2.2 INCREASE IN TREND OF USING HOME REMEDIES/PHYTOCHEMICALS

6.3 OPPORTUNITIES

6.3.1 INCREASE IN THE ENVIRONMENTAL POLLUTION

6.3.2 AWARENESS OF THE USE OF OTC PRODUCTS

6.3.3 RELAXATION OF RULES ON DIRECT-TO-CONSUMER ADVERTISING

6.4 CHALLENGES

6.4.1 INCREASE IN ABUSE POTENTIAL

6.4.2 INTELLECTUAL PROPERTY RIGHTS LAW

7 MEXICO SPECIFIC POLLEN ALLERGIES MARKET, BY DRUG TYPE

7.1 OVERVIEW

7.2 ANTIHISTAMINE

7.2.1 ANTIHISTAMINE, BY DRUG TYPE

7.2.2 LEVOCETIRIZINE

7.2.3 CETIRIZINE

7.2.4 LORATIDINE

7.2.5 DIPHENHYDRAMINE

7.2.6 CHLORPHENIRAMINE

7.2.7 FEXOFENADINE

7.3 CORTICOSTEROIDS

7.3.1 FLUTICASONE PROPIONATE

7.3.2 TRIAMCINOLONE/TRIAMCINOLONE ACETONOID

7.3.3 CROMOLYN SODIUM

7.3.4 OTHERS

7.4 DECONGESTANTS

7.4.1 DECONGESTANTS, BY DRUG TYPE

7.4.2 PSEUDOEPHEDRINE

7.4.3 PHENYLEPHRINE

7.4.4 OXYMETAZOLINE

7.4.5 OTHERS

7.5 ANTICHOLINERGICS

7.5.1 ANTICHOLINERGICS, BY DRUG TYPE

7.5.2 IPRATROPIUM BROMIDE

7.5.3 OTHERS

7.6 OTHERS

8 MEXICO SPECIFIC POLLEN ALLERGIES MARKET, BY PRODUCTS

8.1 OVERVIEW

8.2 INSTRUMENTS

8.2.1 IMMUNO ASSAY ANALYZER

8.2.2 PRODUCTS, BY IMMUNOASSAY ANALYZER

8.3 RADIO IMMUNO ASSAY (RIA)

8.4 COUNTING IMMUNO ASSAY (CIA)

8.5 ENZYME LINKED IMMUNO-SORBENT ASSAYS (ELISA)

8.6 FLUOROIMMNOASSAY (FIA)

8.7 CHEMILUMINESCENCE ASSAY

8.7.1 LUMINOMETERS

8.8 REAGENTS AND KITS

8.9 OTHERS

9 MEXICO SPECIFIC POLLEN ALLERGIES MARKET, BY DIAGNOSTIC TEST

9.1 OVERVIEW

9.2 IN VIVO TEST

9.2.1 IN VIVO TEST, BY DIAGNOSTIC TEST

9.2.2 SKIN PRICK

9.2.2.1 SKIN PRICK, BY DIAGNOSTIC TEST

9.2.2.2 GREER PRICK

9.2.3 THE STELLAR POINT

9.2.4 PHAZET

9.2.5 BIFURCATED SMALLPOX VACCINATION TEST

9.2.6 23G INTRAVENOUS NEEDLE

9.2.7 OTHERS

9.2.8 PATCH TEST

9.2.9 INTRADERMAL TEST

9.3 IN VITRO TEST

9.3.1 IN VITRO TEST, BY DIAGNOSTIC TEST

9.3.2 SERUM SPECIFIC IGE ASSAY

9.3.3 TOTAL IGE ASSAY

9.3.4 BASOPHIL ACTIVATION TEST

10 MEXICO SPECIFIC POLLEN ALLERGIES MARKET, BY END USER

10.1 OVERVIEW

10.2 HOSPITALS

10.3 DIAGNOSTICS LABORATORIES

10.4 ACADEMIC AND RESEARCH INSTITUTES

10.5 OTHERS

11 MEXICO SPECIFIC POLLEN ALLERGIES MARKET, BY DISTRIBUTION CHANNEL

11.1 OVERVIEW

11.2 DIRECT TENDER

11.3 RETAIL SALES

11.3.1 RETAIL SALES, BY TYPE

11.3.2 HOSPITAL PHARMACY

11.3.3 RETAIL PHARMACY

11.3.4 ONLINE PHARMACY

12 MEXICO SPECIFIC POLLEN ALLERGIES MARKET: COMPANY LANDSCAPE

12.1 COMPANY SHARE ANALYSIS: MEXICO SPECIFIC POLLEN ALLERGIES MARKET

13 SWOT ANALYSIS

14 COMPANY PROFILE

14.1 GLAXOSMITHKLINE PLC

14.1.1 COMPANY SNAPSHOT

14.1.2 REVENUE ANALYSIS

14.1.3 PRODUCT PORTFOLIO

14.1.4 RECENT DEVELOPMENTS

14.2 JOHNSON & JOHNSON SERVICES, INC

14.2.1 COMPANY SNAPSHOT

14.2.2 REVENUE ANALYSIS

14.2.3 PRODUCT PORTFOLIO

14.2.4 RECENT DEVELOPMENTS

14.3 PERRIGO COMPANY PLC

14.3.1 COMPANY SNAPSHOT

14.3.2 REVENUE ANALYSIS

14.3.3 PRODUCT PORTFOLIO

14.3.4 RECENT DEVELOPMENTS

14.4 SIEMENS HEALTHCARE GMBH

14.4.1 COMPANY SNAPSHOT

14.4.2 REVENUE ANALYSIS

14.4.3 PRODUCT PORTFOLIO

14.4.4 RECENT DEVELOPMENTS

14.5 THERMO FISHER SCIENTIFIC INC.

14.5.1 COMPANY SNAPSHOT

14.5.2 REVENUE ANALYSIS

14.5.3 PRODUCT PORTFOLIO

14.5.4 RECENT DEVELOPMENT

14.6 BAYER AG

14.6.1 COMPANY SNAPSHOT

14.6.2 REVENUE ANALYSIS

14.6.3 PRODUCT PORTFOLIO

14.6.4 RECENT DEVELOPMENT

14.7 ALCON INC.

14.7.1 COMPANY SNAPSHOT

14.7.2 REVENUE ANALYSIS

14.7.3 PRODUCT PORTFOLIO

14.7.4 RECENT DEVELOPMENTS

14.8 BIOMÉRIEUX, SA.

14.8.1 COMPANY SNAPSHOT

14.8.2 REVENUE ANALYSIS

14.8.3 PRODUCT PORTFOLIO

14.8.4 RECENT DEVELOPMENTS

14.9 CINFA LABORATORIES

14.9.1 COMPANY SNAPSHOT

14.9.2 PRODUCT PORTFOLIO

14.9.3 RECENT DEVELOPMENT

14.1 CIRCASSIA

14.10.1 COMPANY SNAPSHOT

14.10.2 REVENUE ANALYSIS

14.10.3 PRODUCT PORTFOLIO

14.10.4 RECENT DEVELOPMENTS

14.11 EUROIMMUN MEDIZINISCHE LABORDIAGNOSTIKA AG

14.11.1 COMPANY SNAPSHOT

14.11.2 PRODUCT PORTFOLIO

14.11.3 RECENT DEVELOPMENTS

14.12 LINCOLN DIAGNOSTICS, INC.

14.12.1 COMPANY SNAPSHOT

14.12.2 PRODUCT PORTFOLIO

14.12.3 RECENT DEVELOPMENTS

14.13 MINARIS MEDICAL AMERICA, INC.

14.13.1 COMPANY SNAPSHOT

14.13.2 PRODUCT PORTFOLIO

14.13.3 RECENT DEVELOPMENTS

14.14 PRESTIGE CONSUMER HEALTHCARE INC.

14.14.1 COMPANY SNAPSHOT

14.14.2 REVENUE ANALYSIS

14.14.3 PRODUCT PORTFOLIO

14.14.4 RECENT DEVELOPMENT

14.15 QUEST DIAGNOSTICS INCORPORATED

14.15.1 COMPANY SNAPSHOT

14.15.2 REVENUE ANALYSIS

14.15.3 PRODUCT PORTFOLIO

14.15.4 RECENT DEVELOPMENT

14.16 SANOFI

14.16.1 COMPANY SNAPSHOT

14.16.2 REVENUE ANALYSIS

14.16.3 PRODUCT PORTFOLIO

14.16.4 RECENT DEVELOPMENTS

15 QUESTIONNAIRE

16 RELATED REPORTS

List of Table

TABLE 1 LEVOCETIRIZINE / MONTELUKAST- GLENMARK PHARMACEUTICALS LIMITED

TABLE 2 LEVOCETIRIZINE AND MONTELUKAST-

TABLE 3 DRUGS IN MEXICO SHOULD BE REGISTERED (SANITARY REGISTRY/HEALTH RECORD) WITH COFEPRIS BEFORE MARKETING IN MEXICO.

TABLE 4 MEXICO SPECIFIC POLLEN ALLERGIES MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)

TABLE 5 MEXICO ANTIHISTAMINE DRUG TYPE IN SPECIFIC POLLEN ALLERGIES MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)

TABLE 6 MEXICO ANTIHISTAMINE DRUG TYPE IN SPECIFIC POLLEN ALLERGIES MARKET, BY DRUG TYPE, 2020-2029 (UNITS)

TABLE 7 MEXICO CORTICOSTEROIDS DRUG TYPE IN SPECIFIC POLLEN ALLERGIES MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)

TABLE 8 MEXICO CORTICOSTEROID DRUG TYPE IN SPECIFIC POLLEN ALLERGIES MARKET, BY DRUG TYPE, 2020-2029 (UNITS)

TABLE 9 MEXICO DECONGESTANTS DRUG TYPE IN SPECIFIC POLLEN ALLERGIES MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)

TABLE 10 MEXICO DECONGESTANTS DRUG TYPE IN SPECIFIC POLLEN ALLERGIES MARKET, BY DRUG TYPE, 2020-2029 (UNITS)

TABLE 11 MEXICO ANTICHOLINERGIC DRUG TYPE IN SPECIFIC POLLEN ALLERGIES MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)

TABLE 12 MEXICO ANTICHOLINERGICS DRUG TYPE IN SPECIFIC POLLEN ALLERGIES MARKET, BY DRUG TYPE, 2020-2029 (UNITS)

TABLE 13 MEXICO SPECIFIC POLLEN ALLERGIES MARKET, BY PRODUCTS, 2020-2029 (USD MILLION)

TABLE 14 MEXICO INSTRUMENTS IN SPECIFIC POLLEN ALLERGIES MARKET, BY PRODUCTS, 2020-2029 (USD MILLION)

TABLE 15 MEXICO IMMUNO ASSAY ANALYZER IN SPECIFIC POLLEN ALLERGIES MARKET, BY PRODUCTS, 2020-2029 (USD MILLION)

TABLE 16 MEXICO SPECIFIC POLLEN ALLERGIES MARKET, BY DIAGNOSTIC TEST, 2020-2029 (USD MILLION)

TABLE 17 MEXICO IN VIVO TEST IN SPECIFIC POLLEN ALLERGIES MARKET, BY DIAGNOSTIC TEST, 2020-2029 (USD MILLION)

TABLE 18 MEXICO SKIN PRICK TEST IN SPECIFIC POLLEN ALLERGIES MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)

TABLE 19 MEXICO IN VITRO TEST IN SPECIFIC POLLEN ALLERGIES MARKET, BY DIAGNOSTIC TEST, 2020-2029 (USD MILLION)

TABLE 20 MEXICO SPECIFIC POLLEN ALLERGIES MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 21 MEXICO SPECIFIC POLLEN ALLERGIES MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 22 MEXICO RETAIL SALES IN SPECIFIC POLLEN ALLERGIES MARKET, BY TYPE, 2020-2029 (USD MILLION)

List of Figure

FIGURE 1 MEXICO SPECIFIC POLLEN ALLERGIES MARKET: SEGMENTATION

FIGURE 2 MEXICO SPECIFIC POLLEN ALLERGIES MARKET: DATA TRIANGULATION

FIGURE 3 MEXICO SPECIFIC POLLEN ALLERGIES MARKET: DROC ANALYSIS

FIGURE 4 MEXICO SPECIFIC POLLEN ALLERGIES MARKET : COUNTRY VS REGIONAL MARKET ANALYSIS

FIGURE 5 MEXICO SPECIFIC POLLEN ALLERGIES MARKET : COMPANY RESEARCH ANALYSIS

FIGURE 6 MEXICO SPECIFIC POLLEN ALLERGIES MARKET: INTERVIEW DEMOGRAPHICS

FIGURE 7 MEXICO SPECIFIC POLLEN ALLERGIES MARKET: DBMR MARKET POSITION GRID

FIGURE 8 MEXICO SPECIFIC POLLEN ALLERGIES MARKET: MARKET END USER COVERAGE GRID

FIGURE 9 MEXICO SPECIFIC POLLEN ALLERGIES MARKET: VENDOR SHARE ANALYSIS

FIGURE 10 MEXICO SPECIFIC POLLEN ALLERGIES MARKET: SEGMENTATION

FIGURE 11 THE HIGH PREVALENCE OF ALLERGIC RESPONSE AND INCREASING APPROVAL OF NEW PRODUCT IS EXPECTED TO DRIVE THE MEXICO SPECIFIC POLLEN ALLERGIES MARKET IN THE FORECAST PERIOD OF 2022 TO 2029

FIGURE 12 DRUG TYPE SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE MEXICO SPECIFIC POLLEN ALLERGIES MARKET IN 2022 & 2029

FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF MEXICO SPECIFIC POLLEN ALLERGIES MARKET

FIGURE 14 MEXICO SPECIFIC POLLEN ALLERGIES MARKET, BY DRUG TYPE, 2021

FIGURE 15 MEXICO SPECIFIC POLLEN ALLERGIES MARKET, BY PRODUCTS, 2021

FIGURE 16 MEXICO SPECIFIC POLLEN ALLERGIES MARKET, BY DIAGNOSTIC TEST, 2021

FIGURE 17 MEXICO SPECIFIC POLLEN ALLERGIES MARKET, BY END USER, 2021

FIGURE 18 MEXICO SPECIFIC POLLEN ALLERGIES MARKET, BY DISTRIBUTION CHANNEL, 2021

FIGURE 19 MEXICO SPECIFIC POLLEN ALLERGIES MARKET: COMPANY SHARE 2021 (%)

Frequently Asked Questions

The Mexico Specific Pollen Allergies Market is to grow at a CAGR of 6.5% during the forecast by 2029.
On the basis of product, the Mexico Specific Pollen Allergies Market is segmented into Instruments, Reagents and Kits, and others.
By Drug Type (Antihistamines, Decongestants, Corticosteroids, Anticholinergics and Others), Diagnostic Test (In Vivo Test and In Vitro Test), Product (Instruments, Reagents and Kits and Others), End User (Hospitals, Diagnostics Laboratories, Academic and Research Institutes, and Others), Distribution Channel (Direct Tender and Retail Sales) are covered in this report.
a